{"id":713655,"date":"2022-11-21T06:04:48","date_gmt":"2022-11-21T11:04:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/"},"modified":"2022-11-21T06:04:48","modified_gmt":"2022-11-21T11:04:48","slug":"reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/","title":{"rendered":"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8211; RP1208 is in preclinical development for the potential treatment of depression and obesity \u2013<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>&#8211; Composition of matter patents for RP1208 have been granted in key markets around the world including the United States, Europe, China, and Japan \u2013<\/em>\n      <\/p>\n<p align=\"justify\">CUPERTINO, Calif., Nov.  21, 2022  (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced the issuance of a patent covering composition of matter for RP1208 in Canada, adding to its existing protection in key markets around the world. The Canadian patent covers the compositions of novel phenylcycloalkylmethylamine derivatives and the use of the compositions for the treatment of obesity, and related co-morbid conditions and depression and related co-morbid conditions.<\/p>\n<p align=\"justify\">\u201cThis is another important step in building our intellectual property portfolio and advancing our second pipeline compound, triple reuptake inhibitor RP1208 for the potential treatment of depression and obesity,\u201d said Laxminarayan Bhat, Ph.D., Founder, President, and CEO. \u201cWith patents already in key markets worldwide including the United States, Europe, Japan and China, the addition of Canada further enhances the global market potential for RP1208. We look forward to advancing the preclinical development of RP1208 through IND-enabling studies.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Reviva<br \/><\/strong>Reviva\u00a0is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva\u2019s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva\u2019s pipeline currently includes two drug candidates,\u00a0RP5063\u00a0(brilaroxazine) and\u00a0RP1208. Both are new chemical entities discovered in-house.\u00a0Reviva\u00a0has been granted composition of matter patents for both\u00a0RP5063\u00a0and RP1208 in\u00a0the United States\u00a0(U.S.),\u00a0Europe, and several other countries.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<br \/><\/strong>This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company\u2019s Phase 3 RECOVER study and timing of topline data, product development, clinical and regulatory timelines and expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management\u2019s current beliefs and assumptions.\u00a0These statements may be identified by the use of forward-looking expressions, including, but not limited to, \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpotential, \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwould\u201d and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company\u2019s filings with the\u00a0Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>Reviva Pharmaceuticals Holdings, Inc.<br \/>Laxminarayan Bhat, PhD <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZqQF9Pr0kVou_mWnzKdiWxgkrCZtt1KuHJ8VFSdImddkb6FVEA52Fe6JsmObskcaacKlk5g7C8-i2KOJ7ax8HXLS5um9dot2gTnzUYsNQkw=\" rel=\"nofollow noopener\" target=\"_blank\">www.revivapharma.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>LifeSci Advisors, LLC<br \/>Bruce Mackle<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9PA0asrUW9CvL9qtWbaaoIV3nF-Bt2wb725a_po78ofVVstWSWV_5m65eEimO2c8AYYYJQoNQGRwluI0tvNxBN4wV4CovRR5A6Teq80jp8Zu9ETAZoyNbKae8CYXrNGc\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p>RedChip Companies Inc<br \/>Todd McKnight<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gyE1p23gK6-TSu9stWRkACta39cn3xr5fP1gt7BE72efSzvPr3G4fq8ygkil6XPuvEvG33iTH4TWFP_B2oD-Eg==\" rel=\"nofollow noopener\" target=\"_blank\">Todd@redchip.com<\/a><br \/>(917) 349.2175<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGIwNWRkMDItMjAyNy00YmRhLWExYTktYmNjMmI3ZTc2Yzk4LTUwMDA3NTM4MQ==\/tiny\/Reviva-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; RP1208 is in preclinical development for the potential treatment of depression and obesity \u2013 &#8211; Composition of matter patents for RP1208 have been granted in key markets around the world including the United States, Europe, China, and Japan \u2013 CUPERTINO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced the issuance of a patent covering composition of matter for RP1208 in Canada, adding to its existing protection in key markets around the world. The Canadian patent covers the compositions of novel phenylcycloalkylmethylamine derivatives &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-713655","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; RP1208 is in preclinical development for the potential treatment of depression and obesity \u2013 &#8211; Composition of matter patents for RP1208 have been granted in key markets around the world including the United States, Europe, China, and Japan \u2013 CUPERTINO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced the issuance of a patent covering composition of matter for RP1208 in Canada, adding to its existing protection in key markets around the world. The Canadian patent covers the compositions of novel phenylcycloalkylmethylamine derivatives &hellip; Continue reading &quot;Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-21T11:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208\",\"datePublished\":\"2022-11-21T11:04:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/\"},\"wordCount\":608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/\",\"name\":\"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==\",\"datePublished\":\"2022-11-21T11:04:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/","og_locale":"en_US","og_type":"article","og_title":"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208 - Market Newsdesk","og_description":"&#8211; RP1208 is in preclinical development for the potential treatment of depression and obesity \u2013 &#8211; Composition of matter patents for RP1208 have been granted in key markets around the world including the United States, Europe, China, and Japan \u2013 CUPERTINO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced the issuance of a patent covering composition of matter for RP1208 in Canada, adding to its existing protection in key markets around the world. The Canadian patent covers the compositions of novel phenylcycloalkylmethylamine derivatives &hellip; Continue reading \"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/","og_site_name":"Market Newsdesk","article_published_time":"2022-11-21T11:04:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208","datePublished":"2022-11-21T11:04:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/"},"wordCount":608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/","name":"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==","datePublished":"2022-11-21T11:04:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwMDM4MCM1Mjc0MTk5IzUwMDA3NTM4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-announces-canadian-composition-of-matter-patent-for-triple-reuptake-inhibitor-rp1208\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/713655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=713655"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/713655\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=713655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=713655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=713655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}